Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial
Sponsor: The First Affiliated Hospital of University of Science and Technology of China
Summary
The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.
Official title: Safety and Efficacy of Baricitinib Combined With Acute Large Vessel Occlusion Recanalization : A Multicenter, Randomized Controlled Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
750
Start Date
2026-03-17
Completion Date
2028-01-31
Last Updated
2026-03-04
Healthy Volunteers
No
Interventions
2mg Baricitinib
One 2mg Baricitinib tablet and one 2mg placebo tablet are given three times a day, last for 5±2 days.
4mg Baricitinib
Two 2mg Baricitinib tablets are given three times a day, last for 5±2 days.
Placebo
Two 2mg placebo tablets are given three times a day, last for 5±2 days.
Guideline-based therapy
Guideline-based therapy including EVT treatment is determined by the physician.
Locations (1)
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Recruiting
Hefei, Anhui, China